Anti-viral drugs – Definition and brief summary
Anti-viral drugs are those drugs or class of medications that are used specifically for treating viral infections rather than bacterial ones. The era of antiviral drug therapy started with the idoxuridine (IDU) and trifluridine (TFT) even though; effective antibacterial was known in the late 1930s. The discovery of first antiviral compounds did not come until 1960 for the treatment of herpetic keratitis in the form of idoxuridine and methisazone.
Click to view description and TOC: http://www.marketdataforecast.com/market-reports/global-antiviral-drugs-market-1587/
Ever since, the first antiviral drug, idoxuridine was approved in 1963 about 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of nine human infectious diseases such as-
- HIV Infections
- Hepatitis B Virus (HBV) Infections
- Hepatitis C Virus (HCV) Infections
- Herpes Virus Infections
- Influenza Virus Infections
- Human cytomegalovirus Infections
- Varicella-zoster Virus Infections
- Respiratory Syncytial Virus Infections
- Human papilloma Virus Infections
Global Antiviral drugs Market – Its Market Size
The global antiviral drugs market was valued at US$48.3 billion during the year 2015 with an estimated value in terms of revenue, the antiviral drugs market worth is expected to reach US$82.9 billion by the end of 2025 growing at a CAGR of 6.40%. As of now, there is a huge demand for antiviral drugs from the HIV- infected segment, which is higher than others that are expected to remain so for the next few years because of an alarming increase in the cases of HIV infection.
Download free sample report: http://www.marketdataforecast.com/market-reports/global-antiviral-drugs-market-1587/request-sample
The global antiviral drugs market as per the antiviral drugs market global industry analysis is showing a moderate growth in the pharmaceutical market that is expected to grow further due to new drug launches every other day. During the past three decades, a significant progress has been seen in antiviral drugs market especially in the case of those drugs that target the entry and escaping mechanisms of viruses thereby reducing the impact of these viruses on humans leading to improvement in the quality of patients’ lives.
A broad spectrum of antiviral drugs have has helped in the expansion of antiviral drugs market reach. The introduction of the combination of drug therapies with improved pharmacodynamics and pharmacokinetic properties, new global markets and awareness among the public about antiviral drugs is creating new opportunities for the global antiviral drug market.
The generic drugs dominate the antiviral drugs market with HIV drugs accounting for approximately 50% of the total generic drugs. The HIV generics are expected to create a huge demand in the market due to patent expiry of already existing drugs in the market. In addition, the patent expiry would create a huge opportunity for drug companies in generating huge revenues through the new antiviral drugs in the market.
Market Segmentation of antiviral drugs market – A brief scenario
The global antiviral drugs market is segmented based on disease, indication, product type, and distribution channels. Each of the segmentation/subdivisions is shown in a tabulated format for ease of reference as herein below.
|Disease||Product Type||Distribution Channels|
|Hepatitis Virus Infection||Branded||Hospital pharmacy store|
|HIV/AIDS Infection||Generic||Retail pharmacy store|
|Respiratory Virus Infection||Online pharmacy|
Figure: 1 – Market Segmentation of Antiviral Drugs Market
Under the Product Type – the products such as didanosine, stavudime, lamivudine and zidovudine dominate the generic market due to the prevalence of HIV/AIDS with the therapeutic sales accounting for 61% of the total market. It is estimated that the demand for antiviral drugs would remain high due to an alarming increase in the reports of HIV infection especially in low and middle-income countries of Asia-pacific, Africa and Sub-Saharan regions where there are huge number of people on antiretroviral treatment (ART). In about 21 African countries, 2 out of 3 people are receiving HIV treatment and 2 out 3 positive pregnant women are receiving Antiretroviral (ARV) drugs.
In terms of market revenue generation, North America Market occupies the top position having more than 50% share and is expected to remain dominant over the next few years. Asia-Pacific regions followed by the Middle East and African regions are expected to present the promising opportunities for the growth of antiviral drugs market.